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Abstract

Keywords

Background: the evaluation of cartilage thickness has become possible with new techniques such as
musculoskeletal ultrasonography (US) and magnetic resonance imagining (MRI), making the evaluation of
the treatment response and the progression of the disease more accurate. Objective: to evaluate the efficacy
of a Symptomatic Slow Acting Drug for Osteoarthritis using both US and MRI for measuring cartilage
thickness at baseline and after 1 year. Methods: The study included the clinical evaluation of 20 patients at
baseline, at 6 and 12 months as well as imaging exams (US and MRI) at baseline and after 1 year.
Measurements were performed in both knees, in lateral and medial condyles, and in the intercondylar area.
After the baseline visit, patients underwent a SYSADOA treatment which included Harpagophytum
procumbens (HPc) administered on a daily basis, in a specific regimen. Results and discussions: The US
examination permitted the detailed evaluation of the femoral hyaline cartilage thickness, with statistically
significant differences before and after treatment at the level of the medial compartment, both in the
dominant (1.59±0.49 vs. 1.68±0.49, p=0.0013) and non-dominant knee (1.73±0.53 vs. 1.79±0.52, p=0.0106).
The US and the MRI correlated well (r=0.63) and showed no radiographic progression in knee osteoarthritis
after one year of treatment with specific SYSADOA. Moreover, the US showed improvement in the cartilage
thickness of the medial compartment. Conclusions: The combination with HPc could increase the delay in
the radiographic progression of the knee osteoarthritis, with improvement of femoral hyaline cartilage
thickness in the medial and lateral compartment. The US might be an important tool in OA evaluation and
monitoring.


chondroitin sulfate, glucosamine sulfate, Harpagophytum procumbens, ultrasonography, hyaline
cartilage, knee osteoarthritis, MRI

Highlights

 The combination with HPc could be able to delay progression of the knee osteoarthritis.
 US and MRI represent important techniques with comparable results on patients with
osteoarthritis, but with the remark that US is a much cheaper and more accessible tool.

To cite this article: Vreju FA, Ciurea PL, Chisalau BA, Parvanescu CD, Firulescu SC, Turcu-Stiolica A,
Barbulescu AL, Dinescu SC, Dumitrescu CI, Cristina C, Radu L, Dumitrescu D. The effect of glucosamine,
chondroitin and harpagophytum procumbens on femoral hyaline cartilage thickness in patients with knee
osteoarthritis– An MRI versus ultrasonography study. J Mind Med Sci. 2019; 6(1): 162-168. DOI:
10.22543/7674.61.P162168

*Corresponding author: Cristiana Iulia Dumitrescu, Craiova University of Medicine and Pharmacy,
Department of Pharmacology, 2 Petru Rareş Street, Craiova, Romania
E-mail: dumitrescu.cristiana@gmail.com

Florentin A. Vreju et al.

Introduction
Osteoarthritis represents the most frequent type of
articular involvement and is the result of altered metabolic
processes at the level of the joint cartilage, leading to a
higher rate of destruction relative to synthesis. The result
is the thinning of the protective cartilage along with joint
space narrowing, with consecutive pain and functional
impairment in the early stages of the disease, as well as
joint deformities and even ankyloses in later stages.
The treatment for osteoarthritis includes both fast
acting symptomatic drugs (analgesics, nonsteroidal antiinflammatory drugs) and slow acting drugs (SYSADOA –
Symptomatic Slow Acting Drug for Osteoarthritis) – with
a chondrotrophic and chondroprotective roles, such as
glucosamine or chondroitin, involved in the balance
between the synthesis and degradation of cartilage. The
outcome is less pain and improved mobility and
functioning at the joint; however, the effects tend to
appear only after 6 months of treatment (1).
EULAR 2003 guidelines position glucosamine and
chondroitin at the maximum level of evidence for
pharmacological actions in case of knee osteoarthritis,
being classified as 1A for clinical studies and at level A of
recommendation (2, 3). More recently, the 2018 EULAR
update for the management of hand OA includes
chondroitin and chondroitin compounds among the best
nutraceuticals which may be used for the improvement of
articular functioning (4). Most studies (over 300)
evaluated products with a glucosamine/chondroitin rate of
500/400mg, most frequent dosages involving 1500 mg of
glucosamine and 1200 mg of chondroitin, but for a short
period of time, such as 3 to 6 months (5-7).
The American College of Rheumatology (ACR)
conditionally (depending on the site of involvement)
recommended avoiding glucosamine and chondroitin in
cases of osteoarthritis (8), based mostly on the GAIT
study that showed no difference in the joint space
irrespective of the combination administered glucosamine, chondroitin, celecoxib, the combination of
glucosamine and chondroitin, or placebo (9).
Thus, the evaluation of cartilage thickness has become
a requirement in the evaluation of treatment response and
disease progression with the new techniques such as
musculoskeletal ultrasonography (US) or magnetic
resonance imagining (MRI). Currently, although
consensus is lacking, most studies recommend MRI as the
gold standard imaging method in rheumatology, since it
can visualize all articular and peri-articular structures in
great detail (10, 11). US might identify and evaluate

cartilage thickness, as a hypoechoic structure, superficial
to cortical bone (12-15).

Materials and Methods
Objective
The aim of our study was to evaluate the efficacy of a
SYSADOA product that consists of a combination of
500g glucosamine sulfate, 400mg chondroitin sulfate,
10mg collagen type II and 40mg Harpagophytum
procumbens per day (ed.), using both US and MRI to
measure articular thickness. As a secondary objective, we
proposed to confirm the level of agreement between US
and MRI in cartilage thickness measurements.
Patients and Methods
This longitudinal prospective open study included 20
patients, aged 40-75 years, diagnosed with knee
osteoarthritis according to clinical and imaging criteria
(16). Informed consent had been signed and medical
history records were reviewed for previous joint disease
or comorbidities. Patients underwent clinical evaluation,
saving anamnestic and clinical data and establishing the
stage of the disease using Kellgren and Lawrence criteria
(17).
Excluded patients were those with severe knee
osteoarthritis (Kellgren & Lawrence stage 4), aged over
75yr, with local trauma or in need for knee surgery, with
inflammatory joint diseases or organ failure, with a
change in the NSAID treatment in the past week, or with
history of recent use (less than 2 months) of SYSADOA
drugs. Pain was quantified on the VAS scale and
functional impairment was assessed using the WOMAC
osteoarthritis index and HAQ 20 item questionnaires (18).
The study design included clinical evaluation at
baseline, at 6 and 12 months, and imaging exams (US and
MRI) at baseline and after 1 year. After the baseline visit,
which included both clinical and imaging evaluations, the
patients received the SYSADOA treatment which
consisted of a combination of 500g glucosamine sulfate,
400mg chondroitin sulfate, 10mg collagen type II, and
40mg Harpagophytum procumbens administered daily
after lunch, for 2 months, alternated with 2 weeks of
pause. In case of pain, patients were allowed to use escape
medication (500 mg to 3000 mg paracetamol). Patient
adherence was evaluated by counting capsules returned at
each visit.
The ultrasound (US) evaluation
The ultrasound (US) evaluation was performed by
the same examiner, an expert in musculoskeletal
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ultrasonography, using an ESAOTE Biomedica MyLab25
machine, equipped with a 10-18 MHz broadband, linear
array transducer. Each patient was evaluated in grayscale
(GS), being positioned in a supine position with the knees
fully flexed in order to examine the femoral hyaline
cartilage, in both the short and long axis of the femur. The
US was performed according to EULAR guidelines (19).
The hyaline cartilage was identified as a hypoechoic line
of varying thickness, which was lying on top of the
hyperechoic femoral cortical bone, covered by a thin
hyperechoic line, defined as cartilage interface. The
measurements were performed in both knees with the
transducer in transverse scan, in both lateral and medial
condyles, and in the intercondylar area, assuring a sharp
horizontal superficial hyperechoic demarcation of the
cartilage (Figure 1).
Cartilage thickness was recorded and measured in all
three areas. Moreover, any irregularities in the cartilage
and subchondral bone, and any change in the hypoechoic
aspect of the cartilage or in the cartilage interface that
might have been indicative of crystal arthropathies, were
noted. The interpretation of all findings was based on
OMERACT definitions for US pathology (20).
The MRI examination
The scans were performed by an experienced
radiology technician and were analyzed by an expert
radiologist, with over 10 years of experience in
rheumatologic MRI scans, which were both blinded to US
and clinical data. The study was performed on a 1.5 T
MR system (Siemens Magnetom Symphony, 1.5 T)
equipped with CP Flex large coil.
The positioning of the patient in the magnet was
supine with feet forward; the image protocol consisted of:
COR_T2_TIRM, SAG_SE_T1, SAG_PD_TSE_FS and
AX_T2_ME2D. The sequence parameters were: on
COR_T2_TIRM: TR/TE: 7160 / 77; SAG_SE_T1:
TR/TE: 526/12; SAG_PD_TSE_FS: TR/TE: 3960/14;
AX_T2_ME2D: TR/TE: 758/22. The vision field was 170
mm and the slice thickness ranged between 0.5-1.5mm.
The measurement of cartilage thickness was
performed first, on the COR_T2_TIRM sequence at three
sites: in the middle of the medial femoral condyle, of the
lateral femoral condyle, and the intercondylar area. The
same medial and lateral femoral condyles were measured
on SAG_SE_T to confirm the results.
Statistical analysis
Statistical analysis was performed using Graph Pad
Prism 5.00 and data were expressed as the mean ±
standard deviation (SD) unless specified otherwise. The
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values of cartilage thickness in both US and MRI
evaluations were analyzed using paired t-test to verify
differences between dominant and non-dominant sides
and non-paired t-test to compare different imaging
methods. Pearson’s correlation coefficient and linear
regression models assessed the possible correlation
between US findings and variables such as age, HAQ, or
WOMAC. The significance level was set at p  0.05.

Results
The baseline evaluation included 40 knees in 20
patients (11 females and 9 males), with a mean age of
59.3±9.12yo and mean disease duration at the time of
inclusion of 7.35±3.45 years, ranging from to 2 to 15
years. The mean VAS at baseline was 76±9.90 mm.
The US evaluation at baseline revealed that cartilage
loss was more significant in the medial compartment,
especially when compared to the intercondylar area. Thus,
cartilage thickness was significantly higher in the central,
intercondylar area (1.944±0.68 mm) when compared to
the medial compartment (1.50±0.46, p=0.0037).
However, we did not find any statistically significant
differences between the intercondylar area and the lateral
compartment, but a tendency for higher values in cartilage
thickness in the central area (1.944±0.68 vs. 1.708±0.53,
p=0.127). We also did not find any differences between
the dominant versus non-dominant knee.

Figure. 1 A. Ultrasound GS short axis image of the
femoral hyaline cartilage, with the knee fully flexed.
B, C. T2-weighed MRI images of the knee, with
visible femoral cartilage and measurements of
condyles (B) and intercondylar area (C).

Florentin A. Vreju et al.
The MRI measurements correlated well with the
values of cartilage thickness obtained by means of US,
especially for the medial compartment (r=0.63),
suggesting that ultrasonography could be an important
evaluation method for the femoral hyaline cartilage. The
minimal cartilage thickness value was 0.9 mm through
MRI and corresponded to the minimal thickness of 0.83
mm measured through US, in the same patient.
From the point of view of articular functionality, it
seems that there is a strong correlation with cartilage loss
in general and not with specific medial compartment
cartilage thinning (r=0.98). On the other hand, disability
index correlates better with cartilage thickness in the
dominant knee (r=0.82).
Imaging evaluation of treatment response after 1 year
The US and MRI evaluation 1 year after treatment
initiation with combined therapy included 17 patients,
since 3 patients were lost at follow-up: one patient
underwent knee surgery secondary to meniscus and
anterior cruciate ligament lesions, and 2 patients decided
to leave the study for subjective reasons, not related to
medication.

The MRI results showed a difference in the femoral
hyaline cartilage thickness, both in medial and lateral
compartments, with an improvement at this level after the
treatment. Thus, in the medial compartment of the
dominant knee, there was a higher difference between
baseline and 1-year later visit, though still not statistically
significance (p=0.09). Femoral cartilage thickness seems
to improve after SYSADOA treatment, especially in the
non-dominant knee (non-dominant, p=0.05 vs. dominant,
p=0.08).
There was no difference in cartilage thickness before
and after treatment, in the intercondylar area, both for the
dominant (1.316±0.289 vs. 1.30±0.288mm, p=0.824) and
non-dominant knee (1.232±0.264 vs. 1.276±0.258mm,
p=0.500).
The US examination permitted detailed evaluation of
the femoral hyaline cartilage thickness, with a statistically
significant difference before and after treatment at the
level of the medial compartment, both in the dominant
(1.59±0.49 vs. 1.68±0.49, p=0.0013) and non-dominant
knee (1.73±0.53 vs. 1.79±0.52, p=0.0106). The
improvement was even more visible in the lateral
compartment, without depending on the dominant/nondominant joint (Table I).

Table I. US cartilage thickness evolution from baseline to one year
Medial compartment

Intercondylar area

Lateral compartment

Dominant

Non- dominant

Dominant

Non- dominant

Dominant

Nondominant

Baseline

1.59±0.49

1.73±0.53

1.97±0.66

2.07±0.62

1.86±0.51

1.80±0.53

1 year

1.68±0.49

1.79±0.52

1.98±0.64

2.05±0.56

1.99±0.47

1.91±0.50

p

0.0013

0.0106

>0.05

>0.05

0.0002

0.0010

Discussions
This study highlighted two important facts: one
concerning novel possibilities for the treatment of knee
osteoarthritis and the other related to the role of US in the
evaluation of the femoral hyaline cartilage, compared to
the gold standard represented by MRI.
Multiple long-term studies have shown that
glucosamine administration might delay the progression
of knee osteoarthritis (21) and may even determine
modifying changes in the course of the disease
(reversion). The study published in 2002 by Pavelka et
al., which included 202 patients with knee osteoarthritis,
showed that after the daily administration for 3 years of
1500 mg of glucosamine or placebo, the progression of
joint space narrowing was different (+0.04 vs. -0.19) (21).
Regarding the clinical evaluation, the placebo group
showed no significant difference, in comparison with the

active treatment group (13). In 2003, Bruyere et al.
published a study on 212 patients with knee osteoarthritis,
with similar results, with the remark that patients with
mild to moderate disease benefited more after
glucosamine treatment (23).
Most of those studies tested only trophic compounds
(glucosamine, chondroitin), in monotherapy or
combination, without analgesic or anti-inflammatory drug
association. Actually, it was considered that one of the
benefits of SYSADOA treatment was the NSAID and
analgesic drug sparing, in order to limit their
cardiovascular, renal, or gastrointestinal adverse effects.
However, the fact that NSAIDs and even glucocorticoids,
in some specific doses, might influence joint cartilage
metabolism was not evaluated. NSAIDs, especially, seem
to inhibit the proteoglycan synthesis by chondrocytes
(24).
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In the last years, there has been increasing evidence of
the favorable effects of Harpagophytum procumbens on
pain and inflammation as an alternative to NSAIDs, with
an improved safety profile (25). The standardized daily
extract of 60mg Harpagophytum procumbens seems to
have a similar effect as selective COX-2 inhibitors, but
with fewer adverse reactions. It also seems to have a
chondroprotective role by inhibiting NO, TNF-α,
interleukin 1-β, leukotriene formation, and matrix
metalloproteinase (MMP), which are responsible for
cartilage destruction. Nevertheless, the anti-inflammatory
and chondroprotective actions could be explained by
inhibition of lipid peroxidase (26).
Although, the association of those drugs was known, it
was based only on the individual therapeutic properties of
each of these compounds, as there is only one study in the
literature showing that the combination of glucosaminechondroitin-Harpagophytum procumbens could lead to
the inhibition of MMP metabolism (27, 28).
Our study shows an increased delay in the progression
of osteoarthritis, by adding Harpagophytum procumbens
to the known chondroprotective combination of
glucosamine-chondroitin, leading to benefits even before
the 3-year period of treatment.
The other result of the study showed a high level of
agreement between US and MRI measurements of
cartilage thickness, both on condyles and intercondylar
area, in accordance with previous studies (29). Similar to
the study of Pradsgaard et al., we have found constantly
higher values of cartilage thickness measured by MRI,
compared to the US-measured ones, a fact that could be
explained by the higher sound speed inside the cartilage,
in comparison with other tissues (roughly 1696m/s vs
1540m/s) (29). Pradsgaard et al. suggested multiplying
the results of the US measurement by 1.10 in order to
obtain an accurate cartilage thickness, a finding confirmed
by our study. Thus, our study also revealed no differences
in the speed of sound within cartilage when comparing
the US results to the MRI results. Therefore, once again,
US might prove an important and accessible tool in the
diagnosis and evaluation of osteoarthritis, besides other
inflammatory and non-inflammatory joint diseases (30,
31).
We are aware of the limitations of this work. Because
participants were drawn from a single center, the study
risks selection bias. Moreover, our study is not placebocontrolled and is limited to the small number of patients
evaluated by a single US examiner, but it can be
considered a pilot for further extension research, with
intra- and inter-reliability studies.
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Conclusions
The combination of 500g glucosamine sulfate, 400mg
chondroitin sulfate, 10mg collagen type II and 40mg
Harpagophytum procumbens determined a delay in the
radiographic progression of knee osteoarthritis, in all
compartments, with improvement of the femoral hyaline
cartilage thickness in the medial and lateral compartment,
visible both through US and MRI imaging techniques.
Furthermore, US and MRI represent important
techniques, with comparable results in the diagnosis,
evaluation, treatment, and monitoring of patients with
osteoarthritis, but with the remark that US is a much less
costly and more accessible tool which offers the
possibility of multiple joint evaluation.
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